Efficacy and safety of RET-TKI in advanced RET-rearranged non-small cell lung cancer in China: a real-world retrospective chart review
RET-TKI had favorable efficacy and safety in real-world contexts in China and should be considered the preferred choice for first-line treatment in RET-rearranged NSCLC patients.
Authors
- Junling Li (ORCID: https://orcid.org/0000-0002-3394-2008)
- Haiyan Xu (ORCID: https://orcid.org/0000-0002-7287-9048)
- Xingsheng Hu (ORCID: https://orcid.org/0000-0002-6652-2384)
- Siyu Lei
- Linyan Tian
- Xuezhi Hao (ORCID: https://orcid.org/0000-0002-2846-2501)
- Yaning Yang (ORCID: https://orcid.org/0009-0005-8173-9396)
- Yang Lu (ORCID: https://orcid.org/0009-0008-1754-3382)
- Yan Wang (ORCID: https://orcid.org/0000-0002-1743-6383)
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Peking University (CN)
- National Cancer Center (US)
- Beijing Chest Hospital (CN)
- Peking University Third Hospital (CN)
Publication Details
- Journal
- BMC Cancer
- Published
- 2024-11-19
- DOI
- https://doi.org/10.1186/s12885-024-13155-z
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00